A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Latest Information Update: 05 Feb 2024
At a glance
- Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.
- 29 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Mar 2024.
- 24 Oct 2022 Status changed from recruiting to active, no longer recruiting.